Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-p 1:50-200, ELISA 1:10000-20000.
Purification:The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Cytotoxic T-lymphocyte protein 4
Cytotoxic T-lymphocyte-associated antigen 4
CD antigen CD152
Buffer form:PBS, pH 7.4, containing 0.02% sodium azide as preservative and 50% glycerol as stabilizer.
Storage conditions:Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Delivery conditions:Gel pack with blue ice.
Immunogen:Synthesized peptide derived from part region of human CD152 protein at amino acid sequence of 41-90
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in CTLA4 have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.